SCI Pharmtech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
November 04, 2021
Share
SCI Pharmtech, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported sales was TWD 228.25 million compared to TWD 678.84 million a year ago. Revenue was TWD 228.25 million compared to TWD 678.84 million a year ago. Net income was TWD 29.92 million compared to TWD 188.92 million a year ago. Basic earnings per share from continuing operations was TWD 0.31 compared to TWD 1.98 a year ago. Diluted earnings per share from continuing operations was TWD 0.31 compared to TWD 1.97 a year ago.
For the nine months, sales was TWD 728.45 million compared to TWD 2,191.09 million a year ago. Revenue was TWD 728.45 million compared to TWD 2,191.09 million a year ago. Net income was TWD 75.34 million compared to TWD 638.92 million a year ago. Basic earnings per share from continuing operations was TWD 0.79 compared to TWD 6.7 a year ago. Diluted earnings per share from continuing operations was TWD 0.79 compared to TWD 6.64 a year ago.
SCI Pharmtech, Inc. is a Taiwan-based company principally engaged in the processing, manufacture and sales of Active Pharmaceutical Ingredients (APIs). The Company's main products include APIs, API intermediates and special and precision chemicals. The Company distributes its products in domestic market and to overseas markets, including Europe, the Americas, the rest areas of Asia and others
SCI PHARMTECH, INC. 
